NXT007 enhances in vitro coagulation potential in the coexistence of emicizumab in hemophilia A through distinct complex formation

Background: NXT007 is a factor (F)VIIIa-mimetic bispecific antibody (BsAb) for hemophilia A (HA), engineered from emicizumab. It is designed to achieve non-hemophiliac levels of plasma coagulation potential and is currently under clinical development. In the future, emicizumab users may switch to NX...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Kazuki Yamaguchi, Kenta Haraya, Hikaru Koga, Kei Nishimura, Keito Inaba, Masaru Muraoka, Atsushi Muto, Takehisa Kitazawa
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-11-01
Saila:	Research and Practice in Thrombosis and Haemostasis
Gaiak:	bispecific antibody emicizumab hemophilia A non-factor replacement therapy NXT007
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2475037925005606
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!